Debt-to-equity of UroGen Pharma Ltd. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
UroGen Pharma Ltd. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • UroGen Pharma Ltd. Debt-to-equity for the quarter ending 30 Sep 2025 was -451%, a 78% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

UroGen Pharma Ltd. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -451% +1593% +78% 30 Sep 2025
Q2 2025 -948% -118% -14% 30 Jun 2025
Q1 2025 196576% +196910% 31 Mar 2025
Q4 2024 15426% +15687% 31 Dec 2024
Q3 2024 -2044% -1805% -755% 30 Sep 2024
Q2 2024 -830% -614% -284% 30 Jun 2024
Q1 2024 -334% -65% -24% 31 Mar 2024
Q4 2023 -260% +113% +30% 31 Dec 2023
Q3 2023 -239% +357% +60% 30 Sep 2023
Q2 2023 -216% +3023% +93% 30 Jun 2023
Q1 2023 -269% -894% -143% 31 Mar 2023
Q4 2022 -373% -566% -294% 31 Dec 2022
Q3 2022 -596% -691% -729% 30 Sep 2022
Q2 2022 -3239% -3286% -7030% 30 Jun 2022
Q1 2022 625% +606% +3131% 31 Mar 2022
Q4 2021 193% +177% +1130% 31 Dec 2021
Q3 2021 95% +82% +638% 30 Sep 2021
Q2 2021 47% +36% +339% 30 Jun 2021
Q1 2021 19% +10% +117% 31 Mar 2021
Q4 2020 16% +8% +109% 31 Dec 2020
Q3 2020 13% +6% +77% 30 Sep 2020
Q2 2020 11% +3% +44% 30 Jun 2020
Q1 2020 9% +1% +14% 31 Mar 2020
Q4 2019 8% -1% -10% 31 Dec 2019
Q3 2019 7% 0% +0.69% 30 Sep 2019
Q2 2019 7% 30 Jun 2019
Q1 2019 8% 31 Mar 2019
Q4 2018 8% 31 Dec 2018
Q3 2018 7% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.